Iridium-192 curietherapy for T1 and T2 epidermoid carcinomas of the floor of mouth
- Hopital Henri Mondor, Creteil (France)
From 1970 to 1986, 117 patients with T1 (47) or T2 (70) epidermoid carcinomas of the floor of the mouth (SCC) were treated by iridium-192 implantation (192 Ir). The dose was prescribed according to the Paris System and varied over those years. Follow-up information was available on 116 patients. There were 46 T1N0, 47 T2N0, and 23 T2N1-3. Neck management varied for the 93 N0 patients consisting of surveillance (24 T1, 17 T2) or elective neck dissection (22 T1:all pN-, 30 T2: 20 pN-, 10 pN+). Cause specific survival rates were 94% for T1N0, 61.5% for T2N0, and 28% for T2N1-3 at 5 years. Primary local control was 93.5%, 74.5%, and 65%, respectively, and 98%, 79%, and 65% after salvage. Patients with gingival extension or a tumor size over 3 cm (T2b) had a local control of 50% (9/18) and 58% (15/26), respectively. Nodal control was 93.5% for Stage I, 85% for Stage II, and 48% for T2N1-3 patients. There was no difference in nodal control with regard to treatment policy for Stage I-II patients. There were few complications including three deaths: two from surgery and one from 192 Ir. Nodal status, tumor size defined as T1, T2a (less than or equal to 3 cm), T2b (greater than 3 cm), and gingival extension were the only independent prognostic factors. The management of T1N0 and T2N0 SCC by 192 Ir to a dose of 65 or 70 Gy, using the Paris System, is recommended for lesions 3 cm or less and without gingival extension.
- OSTI ID:
- 6870542
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics; (USA), Vol. 18:6; ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
Long-Term Outcomes of Early-Stage Nasopharyngeal Carcinoma Patients Treated With Intensity-Modulated Radiotherapy Alone
Prognostic factors of local outcome for T1, T2 carcinomas of oral tongue treated by iridium 192 implantation
Related Subjects
CARCINOMAS
RADIOTHERAPY
ORAL CAVITY
IRIDIUM 192
MAN
PATIENTS
RADIATION DOSES
RADIATION SOURCE IMPLANTS
SURVIVAL CURVES
ANIMALS
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BETA-PLUS DECAY RADIOISOTOPES
DAYS LIVING RADIOISOTOPES
DIGESTIVE SYSTEM
DISEASES
DOSES
ELECTRON CAPTURE RADIOISOTOPES
HEAVY NUCLEI
IMPLANTS
INTERNAL CONVERSION RADIOISOTOPES
IRIDIUM ISOTOPES
ISOMERIC TRANSITION
ISOTOPES
MAMMALS
MEDICINE
NEOPLASMS
NUCLEAR MEDICINE
NUCLEI
PRIMATES
RADIATION SOURCES
RADIOISOTOPES
RADIOLOGY
THERAPY
VERTEBRATES
550603* - Medicine- External Radiation in Therapy- (1980-)